EMA positive towards unique Huntington’s drug
The European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion for granting orphan drug designation (ODD) to the drug SOM3355 for the treatment of Huntington’s disease.
The decision made by the EMA’s Committee for Orphan Medical Product (COMP) recognises an ongoing unmet medical need for new and improved treatment options for those living with Huntington’s disease and their families.
SOM3355, which has been developed by SOM Biotech, is a molecule with a unique multimodal mechanism of action being a mild beta-blocker and a VMAT1 and VMAT2 inhibitor. The drug already has ODD designation in the US and has achieved positive results in both proof-of-concept and phase IIb clinical studies in Huntington’s disease.
“Such promise, which must be substantiated in the Phase III clinical study, will resonate not only with patients in Europe but also worldwide,” said Silvia Panigone, CEO of SOM Biotech. “This recognition supports SOM Biotech’s mission to explore the full potential of SOM3355 and to bring a novel first-line treatment option to the Huntington’s disease patients in the EU and beyond.”
Treating Huntington’s disease
Huntington’s disease is a rare, hereditary, progressive neurodegenerative disorder, caused by a trinucleotide CAG-repeat expansion ≥36 in the Huntington gene. The disease is clinically characterised by a triad of symptoms, including motor abnormalities, neuropsychiatric disturbances and cognitive decline.
Huntington’s disease has a complex symptomatology, varying in nature at different stages of the disease. This arises from progressive neurodegeneration and the associated imbalance of neurotransmitters, but there is currently no cure.
Current therapeutic interventions, as in the case of dopamine depleting agents, focus on individual symptoms of the disease’s complex clinical presentation, including motor, behavioural or psychiatric disturbances. This can lead to polypharmacy and associated poor adherence, increased risk of adverse events, exacerbation of symptoms, drug-to-drug interactions and hospitalisation.
“The dynamic nature of Huntington’s disease requires that more medications are prescribed based on disease progression,” said Rossella Medori, MD, CMO of SOM Biotech. “The need to improve quality of care by treating Huntington’s disease in its complexity is now well recognised. If the clinical profile of SOM3355 is confirmed, we hope to offer a streamlined medicinal intervention addressing multiple symptoms with good tolerability that is accepted well by individuals suffering from Huntington’s disease.”
